| Name | Title | Contact Details |
|---|
Unlocking the secrets of life itself is the driving force behind the Salk Institute. Our team of world-class, award-winning scientists pushes the boundaries of knowledge in areas such as neuroscience, cancer research, aging, immunobiology, plant biology, computational biology, and more. Founded by Jonas Salk, developer of the first safe and effective polio vaccine, the Institute is an independent, nonprofit research organization and architectural landmark: small by choice, intimate by nature, and fearless in the face of any challenge.
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders.
We are a biotechnology company creating a new class of targeted gene therapies for debilitating and life-threatening genetic disorders in both central nervous system (CNS) and non-CNS indications. Current gene therapy approaches have shown dramatic efficacy in several rare diseases but are hindered by imprecise targeting. The inability to selectively transduce specific cells and tissues effectively drives administration of higher doses and resulting safety liabilities. We are addressing these concerns with our proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the disease organ while limiting transduction of tissues and cells not relevant to the target disease. Through our next-generation AAV platform combined with cargo development and state-of-the-art manufacturing, we are tackling monogenetic and sporadic CNS and non-CNS disorders that have previously been challenging to address.
C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor`s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.
Ÿnsect is the world leader in the production of protein and natural insect fertilizers. Founded in 2011 in Paris, France, by both scientists and environmental activists, Next40 and B Corp-certified, the company processes insects into high-end, high-value ingredients for pets, fish, plants and humans. From its purpose-built state-of-the-art farms, Ÿnsect offers a long-term, sustainable, organic solution to accelerate protein and plant consumption. Ÿnsect uses pioneering proprietary technology covered by 377 patents across 44 categories, to produce lesser and yellow mealworms in fully automated vertical farms. Ÿnsect runs three production sites, one in Dole, France (commissioned 2016), one in the Netherlands (2017), one in the USA (since 2022), and a third site, the world`s largest vertical farm, in Amiens in France, is currently under construction. The company, which employs 360+ people, has raised around $ 500 million from major global investment funds, banks and public bodies and exports its products around the world.